Paving the way for early diagnosis and intervention in rare MC4R pathway diseases: VENTURE trial results from age 2

IMCIVREE®▼ (setmelanotide) 10 mg/ml subcutaneous solution for injection. Indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 2 years of age and above. Proprietary: Rhythm Pharmaceuticals Netherlands B.V. Tel: +31 20 8546071. 
Authorisation number EU/1/21/1564/0001. Funded by the National Health System and subject to medical prescription. Hospital use. 2,750 €/vial.  Text revised in November 2024. Adverse events should be reported to Rhythm Pharmaceuticals and Pharmacovigilance of Medicinal Products for Human Use: http://www.notificaRAM.es.

▼This drug is subject to additional monitoring. For more information contact https://cima.aemps.es/cima/dochtml/ft/1211564001/FT_1211564001.html.

This webinar is fully organised and funded by Rhythm Pharmaceuticals Netherlands B.V. and is intended for healthcare professionals only. The session will include promotional content on Rhythm products.